Introduction {#s0001}
============

Warfarin is a high-alert medication and a commonly prescribed medicationused by numerous patients for various indications. Due to the many drug--drug, drug--food, and drug--disease interactions and genetic influence on warfarin pharmacodynamics/pharmacokinetics, warfarin doses are highly variable among individuals and regular dosage adjustment inevitable.[@cit0001] Despite the current availability of direct oral anticoagulants (DOACs), which have fewer drug--food interactions with unneeded regular blood-coagulation monitoring, the risk of bleeding associated with some DOACs, burden of high cost, and presence of valvular heart diseases limit the clinical utilization of DOACs, making warfarin still a favorable choice for both clinicians and patients.[@cit0002],[@cit0004]

Anticoagulation with warfarin requires regular international normalized ratio (INR) readings for safety and efficacy monitoring.[@cit0001] The goal of therapy is specified by a therapeutic INR range that is determined based on the clinical indication. Having the INR reading within the therapeutic INR range for particular diseases during follow-up provides an objective parameter for the efficacy and safety of warfarin. However, individual INR readings do not reflect the actual time spent in the therapeutic INR range during the period between visits. Warfarin's efficacy and safety is correlated with actual time spent within the therapeutic INR. Time in therapeutic range (TTR) is an estimate that measures the percentage of actual time spent within the therapeutic INR.[@cit0005] The optimal clinical benefit of warfarin therapy is achieved only when the patient's INR is kept within the therapeutic range, ideally during the entire period. Maintaining TTR at or above 70% is associated with clinical benefit in terms of efficacy and safety.[@cit0006]

The anticoagulation control of warfarin therapy is affected by the clinical judgment of the treating clinician. Pharmacists are known for their role in patient counseling, dose adjustment, and identifying drug--drug, drug--food, and drug--disease interactions.[@cit0007] Our study aimed to investigate differences in anticoagulation control of warfarin utilizing a TTR approach in clinics managed by a clinical pharmacist compared with clinics managed by other health-care providers.

Methods {#s0002}
=======

This prospective observational study ran from June 2017 to July 2018 at King Saud University Medical City (KSUMC) in Riyadh, capital of Saudi Arabia. All adult patients being followed in outpatient anticoagulation clinics to be coagulated with warfarin were candidates for inclusion. Patients on any DOACs, heparin products, or other anticoagulants, or had been admitted during follow-up, visited the emergency department for bleeding that resulted in warfarin being withheld, or crossed over between the study clinics during the study period were excluded. The study was approved by the institutional review board at KSUMC (E-17-2547). Patient consent to review their medical records was not required by the board, because this was an observational, noninterventional prospective study only to collect particular human data and subjects would receive the standard of care regardless. In addition, these patient-related data were collected confidentially and in compliance with the Declaration of Helsinki.

Patients were followed in two anticoagulation clinics: one run by clinical pharmacists and the other by physicians. Ambulatory-care clinical pharmacists supervise the pharmacist-led clinic and hematology consultants the physician-led clinic. In each clinic, patients were randomly allocated and followed for 12 months to assess qualitative differences in anticoagulation control in the two clinics. Patients were followed with INR measurements and warfarin-dose assessment at each visit. Other information were collected through patient-chart reviews, including demographics, disease status and renal function. An institutional protocol for the frequency of INR measurement in cases of dose adjustments was available and approved where the study was conducted. This protocol generally states that INR measurements after dose adjustment should be performed more frequently; however, the frequency of visits is determined and judged by treating clinicians and range from weekly to every 3 months according to the patient's clinical status. For each patient, at least three to four INR readings were collected to be included in calculations using Rosendaal linear interpolation and measured with a computer-based program. Rosendaal linear interpolationis a method used by the vast majority of clinical researchers to calculate TTR.[@cit0008] Good anticoagulation control is defined as TTR ≥70%, while poor anticoagulation control is defined as TTR \<70%. The INR readings included in the TTR measurement were at least 1 month apart (this was to make sure that the INR was stable), and readings separated by more than 1 month were allowed.

Our primary outcome was differences in TTR, measured using Rosendaal linear interpolation, between the pharmacist-led clinic and the physician-led clinic. Patients who were seen by clinical pharmacists during our study were followed retrospectively to measure TTR during the period when the same patients were followed by physicians, and were included as a secondary outcome. Data was analyzed by SPSS version 25.0. Continuous variables are presented as means ± SD and categorical variables as numbers and percentages. Continuous variables were compared between groups using Students' *t*-test or Mann--Whitney *U* test. Categorical variables were compared using χ^2^ or Fisher's exact test. *p*\<0.05 was considered significant.

Results {#s0003}
=======

A total of 62 patients were enrolled from June 2017 to July 2018: 33 patients were followed by the pharmacist-led clinic and 29 by the physician-led clinic. Mean age of patients was 53±2.6 years and 53.2% were male. Baseline characteristics are shown in [Table 1](#t0001){ref-type="table"}. Apart from age and diabetes, which weresignificantly different between patients followed by clinical pharmacists versus those followed by physicians, all other demographic data were comparable between the two groups.Table 1Baseline characteristicsPharmacist (n=33)Physician (n=29)*P*-valueGender, n (%)Male14 (42%)8 (27%)0.223Female19 (58%)21 (83%)0.223Age, years (mean ± SD)58.76±2.0746.86±3.60.002Htn, n (%)14 (42%)9 (31%)0.354DM, n (%)14 (42%)3 (10%)0.009IHD, n (%)6 (18%)6 (20%)0.803CrCl, mL/min (mean + SD)87.55±6.97103.54±8.890.157FU, months (mean±SD)7.88±0.418.55±0.380.238[^1]

The main indication for warfarin use was mitral valve replacement (60% in pharmacist-led arm and 31% in physician-led arm) followed by venous thromboembolism treatment (15%in the pharmacist-led arm and around 17% in the physician-led arm). Other indications are shown in [Table 2](#t0002){ref-type="table"}. Eighteen patients in the pharmacist-led clinic versus 16 in the physician-led clinic had their doses of warfarin changed over the study period (55% in pharmacist-led clinic versus 55% in physician-led clinic, *p*=0.961). The number of changed doses of warfarin occurred in pharmacist-led clinics compared to physician-led clinics is listed in [Table 3](#t0003){ref-type="table"}.Table 2Indications of warfarinMVR\*AVRDVT/PEAfibSLE/APS\*Pharmacists (n=33)20 (60%)3 (9%)5 (15%)4 (12%)1 (3%)Physicians (n=29)9 (31%)4 (13%)5 (17%)4 (13%)7 (24%)[^2][^3] Table 3Changes in warfarin doseNumber of changed doses per patientPharmacist-led clinicsPhysician-led clinicsTotalNo change1513281156212281031124011Total332962[^4]

Mean TTR level was significantly higher among patients in the pharmacist-led clinic than the physician-led clinic (87.27%±3.82% and 52.48%±5.49%, respectively; *p*\<0.001; [Figure 1](#f0001){ref-type="fig"}). Secondary analysis was conducted among the same patients (n=27) followed retrospectively by physicians and prospectively by clinical pharmacists, revealing that TTR was significantly higher duringclinical pharmacist care (91.70%±2.93% versus 61.39%±5.11%, respectively; *p*\<0.001; [Figure 2](#f0002){ref-type="fig"}). On follow-up visits during the study period, approximately 82% of the patient reached their target INR in the pharmacist-led clinic compared to 24% in the physician-led clinic ([Figure 3](#f0003){ref-type="fig"}). No bleeding or thrombotic events were reported during the study period.Figure 1Difference in time in therapeutic range between pharmacist-led and physician-led clinics.Figure 2Difference in time in therapeutic range between pharmacist-led clinic (prospective) and physician-led clinic (retrospective).Figure 3Percentage of patients reaching their target INR.**Abbreviation:** INR, international normalized ratio.

Discussion {#s0004}
==========

Some national guidelines set a target of TTR at 60% or above,[@cit0009],[@cit0010] while others define a TTR range of 58%--65% as acceptable to maximize warfarin efficacy and decrease its toxicity.[@cit0011] Other national guidelines and studies report that maintaining TTR ≥70% is associated with clinical benefit in terms of efficacy and safety.[@cit0008],[@cit0012] In our study, patients followed in the pharmacist-led clinic had higher TTR (87.27%), beyond TTRs in different guidelines, than those followed in the physician-led clinic (52.48%). Also, more patients (82%) followed in the pharmacist-led clinic reached the targeted INR than patients in the physician-led clinic (24%). These results are consistent with other studies conducted globally. A study conducted in an ambulatory-care setting in the US found that pharmacists achieved higher TTR than physicians (66% vs 56.6%, *p*=0.028).[@cit0013] Similar results were seen among Canadian patients, as the TTR for pharmacists was 73% compared to 65% for physicians (*p*\<0.0001).[@cit0014] The superiority of pharmacists in anticoagulation management over physicians utilizing TTR has been reported in clinical trials. Trials conducted in Canada and Hong Kong found that pharmacists attained significantly higher TTR (82% and 64% among Canadian and Hong Kong patients, respectively) than physicians (76% and 59% among Canadian and Hong Kong patients, respectively).[@cit0015],[@cit0016] Furthermore, pharmacist-led anticoagulation clinics were able to improve poor control of warfarin therapy, with TTR \<50%. A study conducted in Brazil assigned patients with TTR \<50% to anticoagulation clinics managed by pharmacists. These clinics had improved TTR readings significantly at 12 weeks postassignment compared to the previous year's TTR.[@cit0017]

Superior pharmacist management of anticoagulation clinics may result from the availability of pharmacists for more frequent coagulation tests, as this is assured by the number of INR readings compared to physicians. In a study conducted by Young et al and another by Shah et al, the number of INR-monitoring tests per year was higher among pharmacists than physicians.[@cit0013],[@cit0014] Also, pharmacist recommendations diminished the number of medication errors, drug interactions, and INR reading outrange, which in turn lead to higher TTR values and greater patients medication adherence.[@cit0018] A study by Aidit et al indicated that pharmacists had a positive influence on management by implementing warfarin medication--adherence clinics ith pharmacists who dedicated some of their time to education, counseling, and dealing with adherence issues.[@cit0019] Furthermore, pharmacists' accessibility for questions and communication influenced the excellent management of anticoagulation that facilitated the establishment of a community pharmacist--led anticoagulation-management service in New Zealand and the development of pharmacist community clinics for anticoagulation in some parts of the US and UK.[@cit0010],[@cit0020],[@cit0021]

In addition to the good management of pharmacist-led anticoagulation clinics, pharmacists in these clinics attain great patient satisfaction by applying valuable interpersonal communication skills and providing essential related information, gaining confidence in their capabilities in dealing with patients from other health-care providers, and providing the service in a cost-effective manner.[@cit0010],[@cit0021] A survey conducted among patients attending community anticoagulation clinics found that pharmacists scored highly on communication (99.4%--99.9% of patients) and information provided (63.1%--94.5% of patients) on such indications as adverse effects, dose adjustment, and medication use.[@cit0021] The health-care cost of pharmacist-led anticoagulation clinics seems lower. It has been estimated that the health-care cost of a pharmacist-led clinic is US\$908.16 compared to \$1,301.76 per patient per year for a physician-led clinic among patients in New Zealand and \$180.21 compared to \$352.29 per patient per 6 months among patients in Malaysia.[@cit0010],[@cit0022]

This study was conducted in single center on a small number of patients, because we followed patients managed solely by either pharmacists or physicians during the whole period of our study. Also, the duration of visits and the education or information provided were not reported. However, the prospective design, parallel comparison, and relatively long follow-up make our study different from most published retrospective studies in the literature. In addition, to our knowledge, this is the first study to evaluate the impact of clinical pharmacists compared to physicians in anticoagulation clinics in an ambulatory-care setting in Saudi Arabia.

Conclusion {#s0005}
==========

Our study found that patients followed in the pharmacist-led clinic had higher TTR levels than those followed in the physician-led clinic.
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[^1]: **Abbreviations:** CrCl, creatinine clearance; DM, diabetes; FU, follow-up; Htn, hypertension; IHD, ischemic heart disease.

[^2]: **Note:** \**p*=0.002).

[^3]: **Abbreviations:** Afib, atrial fibrillation; AVR, aortic valve replacement; DVT/PE, deep- vein thrombosis/pulmonary embolism; MVR, mitral valve replacement; SLE/APS, systemic lupus erythematosus/antiphospholipid syndrome.

[^4]: **Note:** *p*-value for changed doses between pharmacists and physicians was 0.961.
